Thematic Poster
Prognostic variables in lung cancer II
Reactive oxygen species modulator 1 (Romo1) as a diagnostic marker for lung cancer-related malignant effusion
S. Lee(Seoul, Republic of Korea)
COI
1
Rhesus CE expression is an independent prognostic factor in non-small cell lung cancer
A. Schulze(Münster, Germany)
COI
2
Expression of the ILK-PINCH-PARVIN (IPP) complex and its binding partner Rsu-1 in human non-small cell lung cancer
S. Nikou(Patra, Greece)
COI
3
Metaanalysis of ROS1-positive lung cancer cases
R. Zinsky(Wiesbaden, Germany)
COI
4
Expression and clinical significance of S100 calcium binding protein A2 in lung cancer
H. Ren(Xi'an, China)
COI
5
Association between leptin and risk of lung cancer
X. Tong(Chengdu (Sichuan), China)
COI
6
Volatile organic compounds in exhaled breath samples as potential biomarkers in early diagnosis of lung cancer – (Ege translational pulmonology research group [EgeTPAG])
T. Göksel(Izmir, Turkey)
COI
7
Exploiting metabolomic approaches to aid in the diagnosis of lung cancer
L. Mur(Aberystwyth (Dyfed), United Kingdom)
COI
8
Diaphragm invasion worsen the prognosis as indicated in the 8th TNM
Ç. Tezel(Istanbul, Turkey)
COI
9
The effects of polymorphisms identified in genome-wide association studies of never-smoking females on the prognosis of non-small cell lung cancer
S. Yoo(Daegu, Republic of Korea)
COI
10
Comparative analysis of lung cancer driver mutations from FFPE samples and liquid biopsies by IonTorrent next generation sequencing
I. Macovei (Pavel)(Iasi (Iasi), Romania)
COI
11
Interobserver variability of tumor proliferation index and the importance of semiautomated method for counting Ki-67 in lung carcinoma
C. Suciu(Timisoara (Timis), Romania)
COI
12
Enrolment in clinical trials enhances the survival benefit provided to lung cancer patients
C. Fournier(Marseille, France)
COI
13
Development and validation of a prognostic index for survival in patients with non-small-cell lung cancer
G. Soussi(Maisons-Alfort, France)
COI
14
LATE-BREAKING ABSTRACT: Improving the quality of pathological diagnosis of NSCLC in England
N. Navani(London, United Kingdom)
COI
15
LATE-BREAKING ABSTRACT: Treatment efficacy of afatinib vs gefitinib in lung adenocarcinoma with EGFR gene mutation
M. Arroyo Hernandez(Oaxaca, Mexico)
COI
16
. . .